Kaushik Jain, DO
Advanced Heart Failure and Transplant Cardiology · Huntsville, ALNPI 1306134358
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $71,790 of the $80,188 with a category attached, or 89.5%. 21 manufacturers reported payments, led by Boehringer Ingelheim at 38.5% of the total. 2025 is the largest year on record at $22,143, more than ten times the $353 reported in 2019.
Across 200 payments — averaging $400.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$31K
- E.r. Squibb & Sons, L.L.C.$16K
- Lilly USA, LLC$12K
- AstraZeneca$11K
- Pfizer$6K
- Novartis$2K
- plus $3K from 15 others
Across 47 payments — averaging $8461.28 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Endotronix, Inc.$219K
- Eli Lilly$124K
- Bayer$47K
- Novartis$7K
What the payments were for
- Consulting fees$1,6252%
- Speaking & faculty fees$71,79090%
- Travel & lodging$8501%
- Food & beverage$5,9037%
- Education$200%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 30 | $30,859 |
| E.r. Squibb & Sons, L.L.C. | 16 | $16,077 |
| Lilly USA, LLC | 12 | $11,700 |
| AstraZeneca | 27 | $10,693 |
| Pfizer | 23 | $6,204 |
| Novartis | 34 | $1,947 |
| Boston Scientific | 26 | $1,006 |
| Abbott | 10 | $629 |
| Endotronix, Inc. | 3 | $359 |
| United Therapeutics Corporation | 2 | $155 |
| Bridgebio Pharma, Inc. | 1 | $141 |
| Akcea Therapeutics, Inc. | 1 | $125 |
| Amgen | 4 | $62 |
| Sanofi-aventis U.S. LLC | 3 | $56 |
| Actelion Pharmaceuticals US, Inc. | 2 | $47 |
| Impulse Dynamics (USA) Inc. | 1 | $36 |
| Procyrion, Inc. | 1 | $21 |
| Bayer | 1 | $20 |
| Regeneron Healthcare Solutions, Inc. | 1 | $19 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $18 |
| Johnson & Johnson | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- JARDIANCE$42,439
- CAMZYOS$15,603
- FARXIGA$9,975
- VYNDAQEL$5,860
- ENTRESTO$1,325
- WATCHMAN Access System$298
- CARDIOMEMS$238
- CORDELLA PULOMONARY ARTERY PRESSURE SENSOR$169
- Attruby$141
- RESONATE$125
- TEGSEDI$125
- MitraClip System$124
- TYVASO$123
- HeartMate 3 Left Ventricular Assist Device$113
- RESONATE EL ICD VR$106
- BRILINTA$104
How this compares
Too few advanced heart failure and transplant cardiology providers in Alabamato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| WainuaEplontersen Sodium | 30 | $1,508,374 |
| VyndamaxTafamidis | 32 | $954,384 |
| EntrestoSacubitril/Valsartan | 642 | $776,435 |
| JardianceEmpagliflozin | 401 | $465,811 |
| EliquisApixaban | 348 | $375,036 |
| FarxigaDapagliflozin Propanediol | 195 | $215,800 |
| CamzyosMavacamten | 26 | $210,698 |
| Repatha SureclickEvolocumab | 86 | $76,428 |
| MounjaroTirzepatide | 57 | $72,084 |
| TrulicityDulaglutide | 52 | $59,760 |
| OzempicSemaglutide | 32 | $31,139 |
| XareltoRivaroxaban | 13 | $19,577 |
| Isosorbide Dinitrate | 60 | $12,417 |
| CorlanorIvabradine Hcl | 12 | $11,501 |
| VeltassaPatiromer Calcium Sorbitex | 11 | $11,495 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaWainua, Farxiga | $10,693 | $1,724,174225 claims |
| PfizerVyndamax, Eliquis | $6,204 | $1,329,419380 claims |
| NovartisEntresto | $1,947 | $776,435642 claims |
| Boehringer IngelheimJardiance | $30,859 | $465,811401 claims |
| E.r. Squibb & Sons, L.L.C.Camzyos | $16,077 | $210,69826 claims |
| Lilly USA, LLCMounjaro, Trulicity | $11,700 | $131,844109 claims |
| Johnson & JohnsonXarelto | $14 | $19,57713 claims |
| AmgenCorlanor | $62 | $11,50112 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few advanced heart failure and transplant cardiology providers in Alabamaon file to place this against a meaningful peer group, so we don't.
Other advanced heart failure and transplant cardiology in Huntsville
- Kenneth BurnhamMobile$446K
- David SmullDecatur$20K
- Luanda GrazetteMobile$19K
- Indranee RajapreyarBirmingham$6K
- Ayman Haj AsaadBirmingham$5K
- Heriberto Matos SantanaBirmingham$3K
- Jose TallajBirmingham$821
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.